A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs BGB 324 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.
- 09 Jun 2017 Status changed from planning to not yet recruiting.
- 14 Mar 2017 New trial record